Group items tagged

This article discusses a handful of penny stocks with exposure to potential Alzheimer's disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB) and Eisai Co.'s experimental Alzheimer's drug significantly slowed the progression of the disease in a large study. The 18-month, Phase 3 study of 1,800 patients tested the treatment on early-stage Alzheimer's patients. 4 more Alzheimer's stocks to watch

The late stage studies of Bayer's oncology drug, Alpharadin are impressive to say the least. Designed for the treatment of prostate cancer that spreads to the bones, the drug is able to extend life of late-stage patients while minimizing damage to healthy tissue.

Medicinal Cannabis separates itself from many other investments in that it is largely recession proof. While many companies have suffered through a slow recovery General Cannabis has experienced continued growth.

General Cannabis announced their Q2 results and strategies for long-term growth today. The company has been pursuing market dominance in the medicinal cannabis industry.

Convenience and pricing can be a major factor in decision making. WeedMaps recognition of this is clear in their new application for Android.

As the first new Lupus drug to debut in the last half-of-a-century, Benlysta has the potential to be something special. Reception of the drug from doctors has been lukewarm thus far, but with many other treatments associated with severe potential side effects, Benlysta may be a blockbuster nonetheless.